Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Video
A Deep Dive on Tapinarof
Author(s):
In this video interview, Mark Lebwohl, MD, explains why topicals for inflammatory conditions are vital for treatment.
Mark G. Lebwohl, MD, professor of dermatology at Mount Sinai, New York, New York, details how tapinarof cream (GSK2894512; Dermavant), a once-daily topical aryl hydrocarbon receptor (AhR) agonist, is effective for psoriasis, gives his thoughts on the current treatment pipeline, and more in this video interview.
Related Videos
Related Content
